Published in ACS Nano on November 01, 2007
New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev (2010) 3.35
Pre-clinical whole-body fluorescence imaging: Review of instruments, methods and applications. J Photochem Photobiol B (2009) 3.31
Multifunctional nanoparticles as coupled contrast agents. Nat Commun (2010) 2.23
Synthesis and in vivo fate of zwitterionic near-infrared fluorophores. Angew Chem Int Ed Engl (2011) 2.19
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest (2011) 1.91
Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals. Chem Soc Rev (2011) 1.36
In vivo real-time, multicolor, quantum dot lymphatic imaging. J Invest Dermatol (2009) 1.26
Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection. Bioconjug Chem (2009) 1.23
Multicolor imaging of lymphatic function with two nanomaterials: quantum dot-labeled cancer cells and dendrimer-based optical agents. Nanomedicine (Lond) (2009) 1.15
Clinically-translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions. Integr Biol (Camb) (2013) 1.10
Target-to-background enhancement in multispectral endoscopy with background autofluorescence mitigation for quantitative molecular imaging. J Biomed Opt (2014) 1.07
Clinical implications of near-infrared fluorescence imaging in cancer. Future Oncol (2009) 1.07
Quantum dots for cancer research: current status, remaining issues, and future perspectives. Cancer Biol Med (2012) 1.07
Preclinical lymphatic imaging. Mol Imaging Biol (2011) 1.06
In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specific affibody molecule labeled with a near-infrared fluorophore. Neoplasia (2010) 1.04
Molecular probes for the in vivo imaging of cancer. Mol Biosyst (2009) 1.01
Biologically optimized nanosized molecules and particles: more than just size. Bioconjug Chem (2011) 1.00
New approaches to lymphatic imaging. Lymphat Res Biol (2009) 0.99
Simultaneous mapping of pan and sentinel lymph nodes for real-time image-guided surgery. Theranostics (2014) 0.98
Emerging role of radiolabeled nanoparticles as an effective diagnostic technique. EJNMMI Res (2012) 0.96
Dendrimer-based contrast agents for molecular imaging. Curr Top Med Chem (2008) 0.94
Advances in lymphatic imaging and drug delivery. Adv Drug Deliv Rev (2011) 0.94
Multiplexed imaging in cancer diagnosis: applications and future advances. Lancet Oncol (2010) 0.92
A fast and selective near-infrared fluorescent sensor for multicolor imaging of biological nitroxyl (HNO). J Am Chem Soc (2014) 0.91
Mitigating fluorescence spectral overlap in wide-field endoscopic imaging. J Biomed Opt (2013) 0.90
Self-illuminating in vivo lymphatic imaging using a bioluminescence resonance energy transfer quantum dot nano-particle. Contrast Media Mol Imaging (2010) 0.90
Near-infrared molecular probes for in vivo imaging. Curr Protoc Cytom (2012) 0.88
Gadolinium MRI contrast agents based on triazine dendrimers: relaxivity and in vivo pharmacokinetics. Bioconjug Chem (2012) 0.86
Dendrimers in medical nanotechnology. IEEE Eng Med Biol Mag (2009) 0.86
A polymeric fastener can easily functionalize liposome surfaces with gadolinium for enhanced magnetic resonance imaging. ACS Nano (2013) 0.86
In vivo molecular imaging using nanomaterials: general in vivo characteristics of nano-sized reagents and applications for cancer diagnosis. Mol Membr Biol (2010) 0.85
Real-time optical imaging using quantum dot and related nanocrystals. Nanomedicine (Lond) (2010) 0.84
Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry. Mol Pharm (2013) 0.84
Impact of molecular weight on lymphatic drainage of a biopolymer-based imaging agent. Pharmaceutics (2012) 0.84
Lymphatic imaging: focus on imaging probes. Theranostics (2015) 0.83
Guiding principles in the design of molecular bioconjugates for vaccine applications. Bioconjug Chem (2015) 0.81
Modular 'click-in-emulsion' bone-targeted nanogels. Adv Mater (2012) 0.81
NEAR-INFRARED DYES: Probe Development and Applications in Optical Molecular Imaging. Curr Org Synth (2011) 0.81
Exogenous near-infrared fluorophores and their applications in cancer diagnosis: biological and clinical perspectives. Expert Opin Med Diagn (2011) 0.80
Multicolour single molecule imaging in cells with near infra-red dyes. PLoS One (2012) 0.79
Dual-modality imaging with 99mTc and fluorescent indocyanine green using surface-modified silica nanoparticles for biopsy of the sentinel lymph node: an animal study. EJNMMI Res (2013) 0.79
Autofluorescence-free in vivo multicolor imaging using upconversion fluoride nanocrystals. Lasers Med Sci (2009) 0.77
Synthesis and evaluation of a targeted nanoglobular dual-modal imaging agent for MR imaging and image-guided surgery of prostate cancer. Pharm Res (2013) 0.77
Universal Molecular Scaffold for Facile Construction of Multivalent and Multimodal Imaging Probes. Bioconjug Chem (2016) 0.77
Polychromatic in vivo imaging of multiple targets using visible and near infrared light. Adv Drug Deliv Rev (2012) 0.77
Intraoperative mapping of sentinel lymph node metastases using a clinically translated ultrasmall silica nanoparticle. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.75
Different patterns of nuclear and mitochondrial penetration by the G3 PAMAM dendrimer and its biotin-pyridoxal bioconjugate BC-PAMAM in normal and cancer cells in vitro. Int J Nanomedicine (2015) 0.75
Triple-doped KMnF3:Yb(3+)/Er(3+)/Tm(3+) nanocubes: four-color upconversion emissions with strong red and near-infrared bands. Sci Rep (2015) 0.75
Salicylic Acid Conjugated Dendrimers Are a Tunable, High Performance CEST MRI NanoPlatform. Nano Lett (2016) 0.75
Multifunctional Nanomaterials and Their Applications in Drug Delivery and Cancer Therapy. Nanomaterials (Basel) (2015) 0.75
Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol (2003) 11.09
In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol (1999) 8.46
A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ Health Perspect (2006) 6.66
The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer (2005) 5.83
Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer (2006) 3.86
A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res (2003) 2.55
Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett (2007) 2.46
Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjug Chem (2002) 2.45
Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev (2005) 2.33
Long-term exposure to CdTe quantum dots causes functional impairments in live cells. Langmuir (2007) 2.09
PET/CT: form and function. Radiology (2007) 1.89
Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett (2006) 1.80
Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe. J Biomed Opt (2005) 1.70
Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst (2004) 1.55
Fluorescently detectable magnetic resonance imaging agents. Bioconjug Chem (1998) 1.49
3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties. Magn Reson Med (2001) 1.49
Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. Cancer Res (2003) 1.43
An improved, computer-based method to automatically track internal and external diameter of isolated microvessels. Microcirculation (2005) 1.32
Simultaneous two-color spectral fluorescence lymphangiography with near infrared quantum dots to map two lymphatic flows from the breast and the upper extremity. Breast Cancer Res Treat (2006) 1.23
Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. Invest Radiol (1997) 1.14
Characterization of novel histidine-tagged Tat-peptide complexes dual-labeled with (99m)Tc-tricarbonyl and fluorescein for scintigraphy and fluorescence microscopy. Bioconjug Chem (2002) 1.10
Near infrared optical applications in molecular imaging. Earlier, more accurate assessment of disease presence, disease course, and efficacy of disease treatment. IEEE Eng Med Biol Mag (2004) 0.99
Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies. J Nucl Med (1998) 0.97
Sentinel lymph node biopsy and melanoma biology. Clin Cancer Res (2006) 0.95
3D MR angiography of intratumoral vasculature using a novel macromolecular MR contrast agent. Magn Reson Med (2001) 0.90
Sentinel node staging of early breast cancer using lymphoscintigraphy and the intraoperative gamma-detecting probe. Semin Nucl Med (2000) 0.89
Sentinel lymph node biopsy as the new standard of care in the surgical treatment for breast cancer. Expert Rev Anticancer Ther (2006) 0.89
The role of heparanase in lymph node metastatic dissemination: dynamic contrast-enhanced MRI of Eb lymphoma in mice. Neoplasia (2005) 0.87
Lymphography--current role in oncology. Br J Radiol (1991) 0.81
Sentinel lymph node biopsy in melanoma. J Nucl Med (2006) 0.80
Preoperative imaging in primary hyperparathyroidism. Role of thallium-technetium subtraction scintigraphy. Arch Otolaryngol Head Neck Surg (1989) 0.80
Sentinel lymph node biopsy in breast cancer. Methods Mol Med (2006) 0.79
Scintigraphic detection of neural-cell-derived small-cell lung cancer using glioma-specific antibody. J Cancer Res Clin Oncol (1994) 0.79
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Imaging of angiogenesis: from microscope to clinic. Nat Med (2003) 5.51
Rapid cancer detection by topically spraying a γ-glutamyltranspeptidase-activated fluorescent probe. Sci Transl Med (2011) 4.72
Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol (2013) 4.64
Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species. J Biol Chem (2002) 4.54
Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond) (2008) 4.08
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88
New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev (2010) 3.35
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med (2008) 3.15
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology (2010) 3.12
Imaging prostate cancer: a multidisciplinary perspective. Radiology (2007) 2.79
Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med (2011) 2.76
betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol (2008) 2.75
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A (2007) 2.71
Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol (2013) 2.62
Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol (2012) 2.59
Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol (2012) 2.55
In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res (2009) 2.51
Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett (2007) 2.46
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med (2012) 2.42
Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology (2010) 2.38
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood (2004) 2.27
Toxicity of organic fluorophores used in molecular imaging: literature review. Mol Imaging (2009) 2.21
MRI of tumor angiogenesis. J Magn Reson Imaging (2007) 2.19
Highly sensitive fluorescence probes for nitric oxide based on boron dipyrromethene chromophore-rational design of potentially useful bioimaging fluorescence probe. J Am Chem Soc (2004) 2.12
D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol (2011) 2.10
In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res (2007) 2.01
Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer (2013) 1.97
Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol (2007) 1.92
Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol (2009) 1.89
Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int (2007) 1.86
Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett (2006) 1.80
Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin Cancer Res (2007) 1.76
Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol (2009) 1.76
Mechanistic background and clinical applications of indocyanine green fluorescence imaging of hepatocellular carcinoma. Ann Surg Oncol (2013) 1.76
Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. Acc Chem Res (2010) 1.74
Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol (2002) 1.74
Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol (2008) 1.68
Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery (2007) 1.67
Radiologic manifestations of Proteus syndrome. Radiographics (2004) 1.66
In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia (2007) 1.65
A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched avidin-rhodamine conjugate. Cancer Res (2007) 1.64
Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res (2006) 1.57
H-type dimer formation of fluorophores: a mechanism for activatable, in vivo optical molecular imaging. ACS Chem Biol (2009) 1.56
Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano (2012) 1.56
Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst (2004) 1.55
In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies. Mol Cancer Ther (2009) 1.55
Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. Bioconjug Chem (2012) 1.55
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 1.47
Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol (2006) 1.46
Imaging of the lymphatic system: new horizons. Contrast Media Mol Imaging (2006) 1.46
An enzymatically activated fluorescence probe for targeted tumor imaging. J Am Chem Soc (2007) 1.46
Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. J Urol (2007) 1.43
Improvement and biological applications of fluorescent probes for zinc, ZnAFs. J Am Chem Soc (2002) 1.43
A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. J Magn Reson Imaging (2007) 1.43
Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU Int (2012) 1.42
Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. Mol Pharm (2009) 1.42
Highly sensitive near-infrared fluorescent probes for nitric oxide and their application to isolated organs. J Am Chem Soc (2005) 1.41
Synthesis, characterization, and biological evaluation of integrin alphavbeta3-targeted PAMAM dendrimers. Mol Pharm (2008) 1.39
Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies. Radiology (2013) 1.39